Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Credo Science LLC manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 3 distinct examiners across 3 distinct art units. PADMAJA S RAO is the busiest examiner for the portfolio, holding 1 pending office action. The data shows a one to one ratio between pending office actions and distinct examiners, with each action residing in a different art unit.
The distribution of 3 pending office actions across 3 distinct examiners suggests a variety of individual examination styles for the company to manage. Because the 3 pending office actions are spread across 3 distinct art units, the company must address different examination practices within the Biotechnology & Pharmaceuticals field. PADMAJA S RAO, as the busiest examiner with 1 pending office action, manages one-third of the current active workload. This 3 distinct examiners and 3 distinct art units structure requires the company to manage 3 separate sets of deadlines and examiner expectations.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
| SASAN, ARADHANA | 1 | 64.6% | +26.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000918 | HEMP SPROUT PRODUCTS AND METHODS FOR PRODUCING SAME | SASAN, ARADHANA | 126d overdue |
| 18263205 | LIMONENE EFFECTS ON TETRAHYDROCANNABINOL (THC)-INDUCED ANXIETY | RAO, PADMAJA S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000918 | HEMP SPROUT PRODUCTS AND METHODS FOR PRODUCING SAME | SASAN, ARADHANA | 126d overdue |
| 18041015 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS | FETTEROLF, BRANDON J | 3d overdue |
| 18263205 | LIMONENE EFFECTS ON TETRAHYDROCANNABINOL (THC)-INDUCED ANXIETY | RAO, PADMAJA S | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1626 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18263205 | LIMONENE EFFECTS ON TETRAHYDROCANNABINOL (THC)-INDUCED ANXIETY | RAO, PADMAJA S | 1627 | §101§102§103DP | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18041015 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS | FETTEROLF, BRANDON J | 1626 | §103 | Non-Final OA | 3d overdue | Pending | Feb 08, 2023 |
| 18000918 | HEMP SPROUT PRODUCTS AND METHODS FOR PRODUCING SAME | SASAN, ARADHANA | 1615 | §103§112 | Final Rejection | 126d overdue | Pending | Dec 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCredo Science LLC has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Padmaja S Rao has the most, with 1 of Credo Science LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
